Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Dare Bioscience (DARE) over the last 10 years, with Q3 2025 value amounting to $5.2 million.

  • Dare Bioscience's Other Non-Current Liabilities rose 1627.6% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 1627.6%. This contributed to the annual value of $4.7 million for FY2024, which is 2126.12% up from last year.
  • According to the latest figures from Q3 2025, Dare Bioscience's Other Non-Current Liabilities is $5.2 million, which was up 1627.6% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Other Non-Current Liabilities registered a high of $5.2 million during Q3 2025, and its lowest value of $1.0 million during Q2 2021.
  • Over the past 4 years, Dare Bioscience's median Other Non-Current Liabilities value was $4.5 million (recorded in 2024), while the average stood at $4.2 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first changed by 0.0% in 2021, then surged by 2126.12% in 2024.
  • Dare Bioscience's Other Non-Current Liabilities (Quarter) stood at $1.0 million in 2021, then soared by 291.37% to $3.9 million in 2023, then rose by 21.26% to $4.7 million in 2024, then increased by 10.0% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $4.9 million for Q2 2025, and $4.7 million during Q1 2025.